CTC Capabilities

The WRAIR CTC is an approximately 8,500 sq ft outpatient facility located on the WRAIR Main Campus. Main features include four exam and procedure rooms, a phlebotomy suite, reception area, three briefing and testing spaces, lab space for sample processing and investigational product preparation with ventilation hood, and refrigerator and freezer (-20 and -80°C) capacity to support temporary storage of trial materials and specimens.

The clinic has eight dedicated multi-person office suites for staff, and a range of configurable cubicle space for visiting collaborators and monitors, all with dedicated internet and/or WiFi access. The clinic also has secure physical storage and current computer systems to support both hard chart and electronic subject records. The facility is fully temperature controlled, able to operate year-round, and can be accessed by subjects via personal vehicle and public transportation.



 

5 - 10 

 
   
 

Studies conducted per year

 
 

10 - 400

 
   
 

Range of participants enrolled per study

 
 

100+

 
   
 

Participants per day at peak capacity

 
 

>150

 
   
 

Studies completed since inception

 



 

Notable Studies

1966–1972

Meningococcal Disease

Described immune response, developed polysaccharide immunogen, and proved efficacy.

1970–1980

Hepatitis B

Demonstrated protective antibodies enabling immunoglobulin preventive.

1980–1990

Hepatitis A

Investigated safety and immunogenicity; led efficacy study among 40,000 Thai children.

1980–2009

Japanese Encephalitis

Supported all stages from tech development to FDA approval.

1995

Cholera

Developed live oral cholera vaccine candidate from Peruvian El Tor strain.

2009

Adenovirus

FDA approved Ad4/Ad7 vaccines; resumed military vaccinations in 2011.

2010

Anthrax

Shifted delivery to intramuscular to reduce dosing.

2016–2017

Zika

Advanced vaccine concept to clinical studies within nine months.

2018

Dengue

Tested safety and immunogenicity of three vaccine formulations.

2019

RTS,S/Malaria

Demonstrated safety and efficacy; adopted by WHO in Africa.

2019

Ebola

Conducted multiple trials; current DRC vaccine shows 97% efficacy.

2019

MERS-CoV

Completed the only Phase I human trial for a MERS vaccine candidate.

2021

COVID-19

Phase I safety and immunogenicity of SpFN vaccines with ALFQ adjuvant.

2024

Hantavirus

Phase I DNA vaccine study published in Vaccines journal.



 
 

Clinical Trials Consortium

The National Capital Region Military Clinical Trials Consortium (NCRMCTC) was established in 2024 to increase collaboration and synergy between DoD clinical trial capabilities within the National Capital Region. The three clinical trials centers are the Walter Reed Army Institute of Research (WRAIR) Clinical Trial Center, the Naval Medical Research Center (NMRC) Clinical Trials Center, and the Uniformed Services Translation Medicine Unit (TMU). These centers each have long and distinguished histories of conducting FDA-regulated clinical trials, with more than 100 years of combined experience.
 
The consortium leverages unique aspects of each center to include:

  • WRAIR's co-located Pilot Bioproduction Facility (PBF), insectary, and opportunities for on-site specimen processing

  • NMRC and TMU’s colocation with Walter Reed National Military Medical Center (WRNMMC) on the NSA Bethesda main campus